|POZEN Announces February 26, 2008 Webcast of Fourth Quarter and Full Year 2007 Results|
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Feb. 12, 2008--POZEN Inc. (NASDAQ: POZN), announced today that it will release fourth quarter and full year 2007 results on February 26, 2008, before the market opens.
The announcement will be followed by a live webcast at 11:00 a.m. Eastern Time with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN's website at www.pozen.com and will be archived and available for replay. The fourth quarter and full year 2007 earnings release will be accessible in the News section of POZEN's website.
POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN's efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for the proposed product candidate Treximet(TM) which is currently under review by the United States Food and Drug Administration for the acute treatment of migraine, and with AstraZeneca for the proposed product candidate PN 400 for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.
CONTACT: POZEN Inc.